Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant.

Literature DB >> 15213177

Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant.

Richard Malley¹, Sarah C Morse, Luciana C C Leite, Ana Paula Mattos Areas, Paulo Lee Ho, Flavia S Kubrusly, Igor C Almeida, Porter Anderson.

Abstract

Intranasal challenge of C57BL/6 mice with Streptococcus pneumoniae serotypes 6B, 14, and 23F produced colonization of the middle ear and NP. Intranasal vaccination with ethanol-killed nonencapsulated cells with adjuvant protected both sites. Of four nontoxic adjuvants tested, the cholera toxin B subunit was most effective and least nonspecifically protective.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15213177 PMCID： PMC427453 DOI： 10.1128/IAI.72.7.4290-4292.2004

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

13 in total

1. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors: R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal: Infect Immun Date: 2001-08 Impact factor: 3.441

2. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection.

Authors: B K Hvalbye; I S Aaberge; M Løvik; B Haneberg
Journal: Infect Immun Date: 1999-09 Impact factor: 3.441

3. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.

Authors: D E Briles; S Hollingshead; A Brooks-Walter; G S Nabors; L Ferguson; M Schilling; S Gravenstein; P Braun; J King; A Swift
Journal: Vaccine Date: 2000-02-25 Impact factor: 3.641

4. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.

Authors: O Takeuchi; A Kaufmann; K Grote; T Kawai; K Hoshino; M Morr; P F Mühlradt; S Akira
Journal: J Immunol Date: 2000-01-15 Impact factor: 5.422

5. Some aspects of the pneumococcal carrier state.

Authors: R Austrian
Journal: J Antimicrob Chemother Date: 1986-07 Impact factor: 5.790

6. Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors: N B Shoemaker; W R Guild
Journal: Mol Gen Genet Date: 1974

7. Contribution of autolysin to virulence of Streptococcus pneumoniae.

Authors: A M Berry; R A Lock; D Hansman; J C Paton
Journal: Infect Immun Date: 1989-08 Impact factor: 3.441

8. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.

Authors: Pamela A Kozlowski; Selvi B Williams; Rebecca M Lynch; Timothy P Flanigan; Rosalyn R Patterson; Susan Cu-Uvin; Marian R Neutra
Journal: J Immunol Date: 2002-07-01 Impact factor: 5.422

9. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.

Authors: Faiza Rharbaoui; Birgit Drabner; Stefan Borsutzky; Urte Winckler; Michael Morr; Barbara Ensoli; Peter F Mühlradt; Carlos A Guzmán
Journal: Eur J Immunol Date: 2002-10 Impact factor: 5.532

10. Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia coli.

Authors: Ana Paula de Mattos Arêas; Maria Leonor Sarno de Oliveira; Celso Raul Romero Ramos; Maria Elisabete Sbrogio-Almeida; Isaías Raw; Paulo Lee Ho
Journal: Protein Expr Purif Date: 2002-08 Impact factor: 1.650

25 in total

Review 1. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors: Richard Malley; Porter W Anderson
Journal: Proc Natl Acad Sci U S A Date: 2012-02-02 Impact factor: 11.205

2. Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.

Authors: Xiuyu Xu; Jiangping Meng; Yiping Wang; Jie Zheng; Kaifeng Wu; Xuemei Zhang; Yibing Yin; Qun Zhang
Journal: J Microbiol Date: 2014-03-29 Impact factor: 3.422

3. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.

Authors: Richard Malley; Krzysztof Trzcinski; Amit Srivastava; Claudette M Thompson; Porter W Anderson; Marc Lipsitch
Journal: Proc Natl Acad Sci U S A Date: 2005-03-21 Impact factor: 11.205

4. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.

Authors: F C Pimenta; E N Miyaji; A P M Arêas; M L S Oliveira; A L S S de Andrade; P L Ho; S K Hollingshead; L C C Leite
Journal: Infect Immun Date: 2006-08 Impact factor: 3.441

5. Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors: Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal: Infect Immun Date: 2017-09-20 Impact factor: 3.441

Review 10. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic.

Authors: Yu-Wen Chien; Keith P Klugman; David M Morens
Journal: J Infect Dis Date: 2010-10-28 Impact factor: 5.226